Further studies will include characterization of these drug targets on hiPSC-Hep derived from patients with the I148M mutation in the patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene, a major genetic risk factor for NAFLD [56,57,58,59]. This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatotic liver disease.